Related Experiment Videos
New therapies in development for autoimmune diseases: their rationale for combination treatment
1Division of Immunology, Stanford University School of Medicine, 306 Ramona Road, Portola Valley, CA 94028, USA.
Springer Seminars in Immunopathology
|July 18, 2001
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Activating and inhibitory FcgammaRs in autoimmune disorders.
Springer seminars in immunopathology·2006
Injecting drugs of abuse and immunity: implications for HIV vaccine testing and efficacy.
Springer seminars in immunopathology·2006
Fcepsilon- and Fcgamma-receptor signaling in diseases.
Springer seminars in immunopathology·2006
Fc gamma receptors and cancer.
Springer seminars in immunopathology·2006
FcgammaRII and multi-system autoimmune disease.
Springer seminars in immunopathology·2006
Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity.
Springer seminars in immunopathology·2006
Fatty Acid Metabolic Reprogramming in Rheumatoid Arthritis: Integrating Inflammation, Resolution Failure, and Joint Destruction.
Journal of inflammation research·2026
Sporadic lymphangioleiomyomatosis with lymphocyte-predominant pleural effusion misdiagnosed as tuberculosis: a case report.
Respiratory medicine case reports·2026
Epitope-Specific Thyroid Peroxidase Antibodies Reveal Functional Heterogeneity Within a Patient-Derived Monoclonal Repertoire.
Clinical and experimental immunology·2026